血清趋化素、脂联素、胱抑素C及FGF23预测慢性肾脏病4-5期患者血液透析后钙磷代谢紊乱的价值

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (813 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the role of serum levels of chemokine levels, adiponectin (ADPN), cystatin C (CysC) and fibroblast growth factor 23 (FGF23) in predicting calcium and phosphorus metabolism disorders in patients with 4-5 stages of chronic kidney disease (CKD) after hemodialysis.Methods One hundred and twelve patients with CKD 4-5 who had been diagnosed and treated with MHD in the Third Medical Center of PLA General Hospital between January 2018 and January 2020 were selected. An America-made kit was used to detect serum levels of chemerin, ADPN, CysC and FGF23 by means of enzyme-linked immunosorbent assay. The relationship between serum chemerin, ADPN, CysC and FGF23 levels and calcium and phosphorus metabolism disorders in hemodialysis patients was analyzed.Results Among the 112 CKD4-5 patients, 19 (16.96%) had calcium and phosphorus metabolism disorders.The serum levels of chemerin, ADPN, CysC and FGF23 in the disorder group were higher than those in the normal group, and the difference was statistically significant (P<0.05).Multiple Logistic regression analysis showed that overexpressions of serum chemerin (OR=2.497, 95%CI 1.150-5.422),ADPN (OR=4.473, 95%CI 1.373-14.574), CysC (OR=28.448, 95%CI 1.469-551.000) and FGF23 (OR=1.140, 95%CI 1.030-1.261) were influencing factors of calcium and phosphorus metabolism disorders in CKD patients (OR>1, P<0.05).The ROC curve suggested that the AUC of serum levels of chemerin, ADPN, CysC and FGF23 used alone or in combination to predict the risk of calcium and phosphorus metabolism disorders among patients under hemodialysis was above 0.80.Conclusions Serum levels of chemerin, ADPN, CysC and FGF23 are closely related to calcium and phosphorus metabolism disorders in CKD patients undergoing MHD treatment,so they can be used as predictors of the risk of such disorders.

Key words： chronic kidney disease hemodialysis calcium and phosphorus metabolism serum chemerin adiponectin cystatin C fibroblast growth factor 23

Received: 14 July 2021

ZTFLH:

R692.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jingjie
	SHI Yushen
	ZHANG Yanxia

Cite this article:

ZHANG Jingjie,SHI Yushen,ZHANG Yanxia. The role of serum chemerin, adiponectin, cystatin and FGF23 levels in predicting calcium and phosphorus metabolism in patients with 4-5 stages of chronic kidney disease after hemodialysis treatment[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2022, 33(2): 129-133.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2022/V33/I2/129

[1]	Wang C,Yang Y,Yuan F,et al. Initiation condition of hemodialysis is independently associated with all-cause mortality in maintenance hemodialysis patients: a retrospective study[J].Blood Purif,2019,48(1): 76-85.
[2]	Komaba H,Wang M,Taniguchi M,et al. Initiation of sevelamer and mortality among hemodialysis patients treated with calcium-based phosphate binders[J].Clin J Am Soc Nephrol,2017,12(9): 1489-1497.
[3]	张宁,曾涛,张侃,等.尿毒清颗粒联合饮食干预对慢性肾功能衰竭患者血清Chemerin、VEGF的影响[J].实用药物与临床,2017,20(10): 1148-1152.
[4]	郑晓彤,刘大军.脂联素对缺血性肾脏病保护作用的研究进展[J].医学综述,2020,26(10): 1904-1908.
[5]	闫奇奇,郝丽,张森.慢性肾脏病患者血清FGF23水平与钙磷代谢及临床相关性[J].安徽医科大学学报,2019,54(5):776-780.
[6]	Webster A C,Nagler E V,Morton R L,et al. Chronic kidney disease[J].Lancet,2017,389(10075):1238-1252.
[7]	陈香美.临床诊疗指南-肾脏病学分册[M].北京:人民卫生出版社,2009:42.
[8]	Pires A,Sobrinho L,Ferreira H G. The calcium/phosphorus homeostasis in chronic kidney disease: from clinical epidemiology to pathophysiology [J]. Acta Med Port,2017,30(6): 485-492.
[9]	Khairallah P,Isakova T,Asplin J,et al. Acid load and phosphorus homeostasis in CKD[J].Am J Kidney Dis,2017,70(4): 541-550.
[10]	Yang X,Bai Q,Li Y,et al. Comparative efficacy and safety of phosphate binders in hyperphosphatemia patients with chronic kidney disease[J].JPEN J Parenter Enteral Nutr,2018,42(4): 766-777.
[11]	Jovanovich A,Kendrick J. Personalized management of bone and mineral disorders and precision medicine in end-stage kidney disease[J].Semin Nephrol,2018,38(4):397-409.
[12]	张道法,陈道军,武伟,等.腹膜透析和血液透析对终末期肾脏疾病患者钙磷代谢及微炎症状态的影响[J].现代生物医学进展,2018,18(17):3360-3364.
[13]	乔诚,程东生,吴险峰,等.钙磷代谢对于维持性腹膜透析患者心力衰竭的影响研究[J].中国血液净化,2019,18(10):664-668.
[14]	赵丹.慢性肾脏病患者血清脂联素含量与肾脏纤维化的相关性研究[D].长春:吉林大学,2021.
[15]	张正芳.血清CysC和β2-MG与CKD分期的相关性研究[D].西宁:青海大学,2013.
[16]	张艳霞.成纤维细胞生长因子23及其在CKD中的意义研究进展[J].国际泌尿系统杂志,2017,37(1):156-159.
[17]	Joana B,Marek S,Elzbieta S,et al.High serum chemerin level in CKD patients is related to kidney function,but not to its adipose tissue overproduction[J].Renal Failure,2015,37(6):1033-1038.
[18]	陈荣荣.脂联素及其受体的肾脏保护作用机制研究进展[J].国际泌尿系统杂志,2019,39(4): 710-713.
[19]	葛启斌,蔡海琴,陈慧英,等.血清NGAL、KIM-1、CysC在肾肿瘤患者中的表达及应用研究[J].中国医师杂志,2017,19(12):1836-1839.
[20]	胡志娟,史亚男,刘琼,等.成纤维细胞生长因子-23与慢性肾脏病患者矿物质代谢紊乱的相关性研究[J].中国现代医学杂志,2019,29(21):95-99.
[21]	Zylla S,Rettig R,Völzke H,et al. Serum chemerin levels are inversely associated with renal function in a general population[J].Clin Endocrinol(Oxf),2018,88(1):146-153.
[22]	代俊伟,唐晓磊.血清中CysC、RBP、Hcy、CRP水平与糖尿病肾病分期相关性研究[J].国际泌尿系统杂志,2020,40(3):385-388.
[23]	黄盈.低钙透析对维持性血液透析患者钙磷代谢及甲状旁腺激素影响的Meta分析[J].中国血液净化,2019,18(1): 21-25.
[24]	Bevc S,Hojs N,Knehtl M,et al. Cystatin C as a predictor of mortality in elderly patients with chronic kidney disease[J].Aging Male,2019,22(1):62-67.
[25]	夏冬梅.血液透析患者FGF23水平与钙磷代谢的相关性分析[J].四川医学,2018,39(7):748-750.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(4): 338-340.